20 Stocks Moving in Friday’s Pre-Market Session
Gainers
Cellect Biotechnology Ltd. (NASDAQ: APOP) rose 59.5% to $8.77 in pre-market trading after the company announced the ApoGraft bone marrow transplantation of the first patient in the US.
Soligenix on Thursday Received FDA Orphan Drug Designation for Hypericin for Treatment of T-cell lymphoma
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=835521
Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical
Soligenix Highlights Publication Demonstrating Successful Formulation And Heat Stabilization Of Filovirus Vaccine Platform For Ebola And Marburg Virus Diseases
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical
SNGX: Positive Preclinical Data for Filovirus Vaccine Candidates…
By David Bautz, PhD
NASDAQ:SNGX
READ THE FULL SNGX RESEARCH REPORT
Soligenix Unveils Preclinical Data From Filovirus Vaccine Candidates
Soligenix Inc (NASDAQ:SNGX) announced positive preclinical data from its filovirus vaccine candidates, including thermostabilized multivalent vaccines in a single vial platform…
Soligenix Announces Preclinical Data With Multiple Heat Stable Filovirus Vaccine Candidates
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical
Soligenix Q2 EPS $(0.05) Up From $(0.10) YoY
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.05) per share. This is a 50 percent increase over losses of $(0.10) per share from the same period last year.